DK1089998T3 - Epothilon-derivater samt deres syntese og anvendelse - Google Patents

Epothilon-derivater samt deres syntese og anvendelse

Info

Publication number: DK1089998T3
Authority: DK; Denmark
Prior art keywords: absent; single bond; synthesis; alkyl; double bond
Prior art date: 1998-06-22

Application number

DK99931120T

Other languages

Danish (da)

English (en)

Inventor

Kyriacos Costa Nicolaou

Yun He

Dionisios Vourloumis

Hans Vallberg

Nigel Paul King

Maurice Raymond Verscho Finlay

Frank Roschangar

Antony Bigot

Original Assignee

Novartis Ag

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-22

Filing date

1999-06-21

Publication date

2007-01-15

1999-06-21 Application filed by Novartis Ag, Scripps Research Inst filed Critical Novartis Ag

2007-01-15 Application granted granted Critical

2007-01-15 Publication of DK1089998T3 publication Critical patent/DK1089998T3/da

Links

230000015572 biosynthetic process Effects 0.000 title abstract 2
150000003883 epothilone derivatives Chemical class 0.000 title abstract 2
238000003786 synthesis reaction Methods 0.000 title abstract 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001301 oxygen Substances 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229930013356 epothilone Natural products 0.000 abstract 1
FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 abstract 1
FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Silicon Polymers (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Lubricants (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK99931120T 1998-06-22 1999-06-21 Epothilon-derivater samt deres syntese og anvendelse DK1089998T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/102,602 US6380394B1 (en)	1996-12-13	1998-06-22	Epothilone analogs

Publications (1)

Publication Number	Publication Date
DK1089998T3 true DK1089998T3 (da)	2007-01-15

Family

ID=22290705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99931120T DK1089998T3 (da)	1998-06-22	1999-06-21	Epothilon-derivater samt deres syntese og anvendelse

Country Status (27)

Country	Link
US (3)	US6380394B1 (de)
EP (2)	EP1741715A1 (de)
JP (1)	JP4681732B2 (de)
KR (3)	KR20090066332A (de)
CN (1)	CN1192031C (de)
AT (1)	ATE343573T1 (de)
AU (1)	AU757854B2 (de)
BR (1)	BR9911420A (de)
CA (1)	CA2334342C (de)
CY (1)	CY1105863T1 (de)
CZ (1)	CZ301783B6 (de)
DE (1)	DE69933767T2 (de)
DK (1)	DK1089998T3 (de)
ES (1)	ES2273502T3 (de)
HU (1)	HUP0102711A3 (de)
ID (1)	ID28210A (de)
IL (3)	IL139784A0 (de)
MX (1)	MXPA00012443A (de)
NO (1)	NO328417B1 (de)
NZ (1)	NZ508622A (de)
PL (1)	PL197648B1 (de)
PT (1)	PT1089998E (de)
RU (1)	RU2227142C2 (de)
SK (2)	SK287864B6 (de)
TR (1)	TR200003844T2 (de)
WO (1)	WO1999067252A2 (de)
ZA (1)	ZA200007059B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE218556T1 (de)	1995-11-17	2002-06-15	Biotechnolog Forschung Gmbh	Epothilon-derivate und deren herstellung
JP4274583B2 (ja)	1996-11-18	2009-06-10	ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ）	エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) *	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6242469B1 (en)	1996-12-03	2001-06-05	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6605599B1 (en) *	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) *	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en)	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
US6380395B1 (en)	1998-04-21	2002-04-30	Bristol-Myers Squibb Company	12, 13-cyclopropane epothilone derivatives
DE19820599A1 (de) *	1998-05-08	1999-11-11	Biotechnolog Forschung Gmbh	Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
KR100851418B1 (ko)	1998-11-20	2008-08-08	코산 바이오사이언시즈, 인코포레이티드	에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
WO2000050423A1 (en) *	1999-02-22	2000-08-31	Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)	C-21 modified epothilones
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
NZ513639A (en)	1999-04-15	2004-02-27	Bristol Myers Squibb Co	Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
AU2508201A (en) *	1999-11-24	2001-06-04	Basf Aktiengesellschaft	Fungicidal melithiazole derivatives
US6518421B1 (en) *	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
WO2001092255A2 (en) *	2000-05-26	2001-12-06	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
AU2001291876C1 (en) *	2000-09-22	2006-11-23	Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)	Triazolo-epothilones
AU2002213248A1 (en) *	2000-10-13	2002-04-22	The University Of Mississipi	Synthesis of epothilones and relates analogs
NZ526871A (en) *	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
EP1353667A1 (de)	2001-01-25	2003-10-22	Bristol-Myers Squibb Company	Parenterale zusammensetzungen enthaltend epothilon-analoge
CZ20032021A3 (cs)	2001-01-25	2004-05-12	Bristol@Myersásquibbácompany	Způsoby podávání analogů epothilonu při léčbě rakoviny
WO2002066038A1 (en)	2001-02-20	2002-08-29	Bristol-Myers Squibb Company	Treatment of refractory tumors using epothilone derivatives
MXPA03007423A (es)	2001-02-20	2003-11-18	Bristol Myers Squibb Co	Derivados de epotilona para tratamiento de tumores refractarios.
KR20030084952A (ko) *	2001-02-27	2003-11-01	게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프)	에포틸론의 분해 및 에티닐 치환된 에포틸론
CA2440555A1 (en)	2001-03-14	2002-09-19	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2002098868A1 (en) *	2001-06-01	2002-12-12	Bristol-Myers Squibb Company	Epothilone derivatives
CA2456280A1 (en) *	2001-08-23	2003-03-06	Novartis Ag	Cyclopropyl and cyclobutyl epothilone analogs
WO2003026744A1 (en) *	2001-09-25	2003-04-03	Alcon, Inc.	The use of epothilones and analogs in conjunction with ophthalmic surgery
DE60224299T2 (de) *	2001-10-25	2008-12-11	Novartis Ag	Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
JP2005511062A (ja) *	2001-12-07	2005-04-28	ノバルティスアクチエンゲゼルシャフト	タンパク質脱アセチル化酵素阻害剤についての生物マーカーとしてのアルファ−チューブリンアセチル化レベルの使用
RU2346686C2 (ru)	2002-01-14	2009-02-20	Новартис Аг	Комбинации, включающие эпотилоны и антиметаболиты
TW200303202A (en) *	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
EP1340498A1 (de) *	2002-03-01	2003-09-03	Schering Aktiengesellschaft	Verwendung von Epothilonen zur Behandlung von mit proliferativen Prozessen assoziierten Gehirnerkrankungen
WO2003077903A1 (en)	2002-03-12	2003-09-25	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
DK1483251T3 (da) *	2002-03-12	2010-04-12	Bristol Myers Squibb Co	C3-cyano-epothilon-derivater
TW200403994A (en) *	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en) *	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US7008936B2 (en)	2002-06-14	2006-03-07	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
BR0313198A (pt) *	2002-08-02	2005-07-12	Novartis Ag	Derivados de epotilona
WO2004018478A2 (en) *	2002-08-23	2004-03-04	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7384964B2 (en) *	2002-08-23	2008-06-10	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
GB0221312D0 (en) *	2002-09-13	2002-10-23	Novartis Ag	Organic compounds
KR20050053681A (ko)	2002-09-23	2005-06-08	브리스톨-마이어스 스큅 컴퍼니	에포틸론 ｂ의 제조, 분리 및 정제 방법, 및 에포틸론 ｂ의ｘ-선 결정 구조
DK1553938T3 (da) *	2002-10-15	2007-03-26	Univ Louisiana State	Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
EP1567487A4 (de)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	Offenkettige, mit prolylharnstoff verwandtemodulatoren der androgenrezeptorfunktion
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
EP1559447A1 (de)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Verwendung von Epothilonen zur Behandlung von neuronalen Konnektivitätsdefekten wie zum Beispiel Schizophrenie und Autismus
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
GB0405898D0 (en) *	2004-03-16	2004-04-21	Novartis Ag	Organic compounds
US10675326B2 (en)	2004-10-07	2020-06-09	The Board Of Trustees Of The University Of Illinois	Compositions comprising cupredoxins for treating cancer
EP1674098A1 (de)	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
JP2008536479A (ja)	2005-02-11	2008-09-11	ユニバーシティオブサザンカリフォルニア	ジスルフィド架橋を有するタンパク質の発現法
JP4954983B2 (ja)	2005-05-18	2012-06-20	ファーマサイエンス・インコーポレイテッド	Ｂｉｒドメイン結合化合物
WO2007015929A2 (en) *	2005-07-27	2007-02-08	University Of Toledo	Epothilone analogues
US8003801B2 (en) *	2005-11-22	2011-08-23	The Scripps Research Institute	Chemical synthesis of a highly potent epothilone
US7653731B2 (en) *	2006-02-24	2010-01-26	Microsoft Corporation	Management of connections to external data
US8008256B2 (en) *	2006-05-01	2011-08-30	University Of Southern California	Combination therapy for treatment of cancer
SG10201407457UA (en)	2006-05-16	2014-12-30	Pharmascience Inc	Iap bir domain binding compounds
KR20090095626A (ko)	2006-12-04	2009-09-09	더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이	쿠프레독신과 ＣｐＧ 리치 ＤＮＡ를 이용한 조성물 및 암 치료 방법
AU2008212788A1 (en)	2007-02-08	2008-08-14	The Board Of Trustees Of The University Of Illinois	Compositions and methods to prevent cancer with cupredoxins
WO2008118327A1 (en) *	2007-03-23	2008-10-02	University Of Toledo	Conformationally restrained epothilone analogues as anti-leukemic agents
EP2065054A1 (de)	2007-11-29	2009-06-03	Bayer Schering Pharma Aktiengesellschaft	Kombinationen mit einem Prostaglandin und Verwendungen davon
DE102007059752A1 (de)	2007-12-10	2009-06-18	Bayer Schering Pharma Aktiengesellschaft	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (de)	2007-12-10	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Nanopartikel mit modifizierter Oberfläche
US20110118343A1 (en) *	2008-07-03	2011-05-19	Pharma Mar, S. A.	Antitumoral Macrolides
US8802394B2 (en)	2008-11-13	2014-08-12	Radu O. Minea	Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (de)	2009-01-27	2010-07-28	Bayer Schering Pharma Aktiengesellschaft	Stabile Polymerzusammensetzung mit einem Epothilon und einem amphiphilischen Blockpolymer
MX340870B (es)	2010-02-12	2016-07-27	Pharmascience Inc	Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
CN103037903A (zh)	2010-05-18	2013-04-10	天蓝制药公司	用于治疗自身免疫性疾病或其它疾病的组合物和方法
BR112013018534B1 (pt)	2011-01-20	2021-04-06	Board Of Regents, The University Of Texas System	Agente de contraste, seus métodos de preparação, e produto de combinação
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
AU2012356894B2 (en)	2011-12-23	2018-01-18	Araris Biotech Ltd.	Enzymatic conjugation of polypeptides
WO2014009426A2 (en)	2012-07-13	2014-01-16	Innate Pharma	Screening of conjugated antibodies
EP2916872B1 (de)	2012-11-09	2019-02-27	Innate Pharma	Kennungen für tgase-vermittelte konjugation
WO2014075391A1 (zh)	2012-11-17	2014-05-22	北京市丰硕维康技术开发有限责任公司	离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
WO2014116594A1 (en) *	2013-01-23	2014-07-31	The University Of Toledo	Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
WO2014140300A1 (en)	2013-03-15	2014-09-18	Innate Pharma	Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en)	2013-06-20	2014-12-24	Innate Pharma	Enzymatic conjugation of polypeptides
JP6744212B2 (ja)	2013-06-21	2020-08-19	イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅＰｈａｒｍａＰｈａｒｍａＳ．Ａ．	ポリペプチドの酵素的結合
WO2017066606A1 (en) *	2015-10-16	2017-04-20	William Marsh Rice University	Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
WO2019092148A1 (en)	2017-11-10	2019-05-16	Innate Pharma	Antibodies with functionalized glutamine residues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW221441B (de) *	1991-01-25	1994-03-01	Taiho Pharmaceutical Co Ltd
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
ATE218556T1 (de)	1995-11-17	2002-06-15	Biotechnolog Forschung Gmbh	Epothilon-derivate und deren herstellung
AU716610B2 (en)	1996-08-30	2000-03-02	Novartis Ag	Method for producing epothilones, and intermediate products obtained during the production process
JP4274583B2 (ja)	1996-11-18	2009-06-10	ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ）	エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6242469B1 (en)	1996-12-03	2001-06-05	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
EP1201666A3 (de)	1997-02-25	2003-03-05	Gesellschaft für biotechnologische Forschung mbH (GBF)	Seitenkettenmodifizierte Epothilone
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
CA2299608A1 (en)	1997-08-09	1999-02-18	Schering Aktiengesellschaft	New epothilone derivatives, method for producing same and their pharmaceutical use
DE19744135C1 (de)	1997-09-29	1999-03-25	Schering Ag	Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

1998
- 1998-06-22 US US09/102,602 patent/US6380394B1/en not_active Expired - Fee Related
1999
- 1999-06-21 AU AU47748/99A patent/AU757854B2/en not_active Ceased
- 1999-06-21 TR TR2000/03844T patent/TR200003844T2/xx unknown
- 1999-06-21 SK SK5009-2007A patent/SK287864B6/sk not_active IP Right Cessation
- 1999-06-21 EP EP06118853A patent/EP1741715A1/de not_active Ceased
- 1999-06-21 PL PL345327A patent/PL197648B1/pl not_active IP Right Cessation
- 1999-06-21 AT AT99931120T patent/ATE343573T1/de active
- 1999-06-21 PT PT99931120T patent/PT1089998E/pt unknown
- 1999-06-21 MX MXPA00012443A patent/MXPA00012443A/es not_active IP Right Cessation
- 1999-06-21 RU RU2000132188/04A patent/RU2227142C2/ru not_active IP Right Cessation
- 1999-06-21 IL IL13978499A patent/IL139784A0/xx unknown
- 1999-06-21 DK DK99931120T patent/DK1089998T3/da active
- 1999-06-21 KR KR1020097010651A patent/KR20090066332A/ko not_active Ceased
- 1999-06-21 US US09/720,070 patent/US6531497B1/en not_active Expired - Fee Related
- 1999-06-21 CA CA2334342A patent/CA2334342C/en not_active Expired - Fee Related
- 1999-06-21 KR KR1020007014546A patent/KR100864742B1/ko not_active Expired - Fee Related
- 1999-06-21 DE DE69933767T patent/DE69933767T2/de not_active Expired - Lifetime
- 1999-06-21 CN CNB998077690A patent/CN1192031C/zh not_active Expired - Fee Related
- 1999-06-21 JP JP2000555904A patent/JP4681732B2/ja not_active Expired - Fee Related
- 1999-06-21 NZ NZ508622A patent/NZ508622A/en not_active IP Right Cessation
- 1999-06-21 ID IDW20002739A patent/ID28210A/id unknown
- 1999-06-21 ES ES99931120T patent/ES2273502T3/es not_active Expired - Lifetime
- 1999-06-21 KR KR1020087011102A patent/KR20080045298A/ko not_active Ceased
- 1999-06-21 CZ CZ20004769A patent/CZ301783B6/cs not_active IP Right Cessation
- 1999-06-21 SK SK1971-2000A patent/SK285647B6/sk not_active IP Right Cessation
- 1999-06-21 WO PCT/EP1999/004287 patent/WO1999067252A2/en not_active Ceased
- 1999-06-21 HU HU0102711A patent/HUP0102711A3/hu unknown
- 1999-06-21 BR BR9911420-8A patent/BR9911420A/pt not_active Application Discontinuation
- 1999-06-21 EP EP99931120A patent/EP1089998B1/de not_active Expired - Lifetime
2000
- 2000-11-20 IL IL139784A patent/IL139784A/en not_active IP Right Cessation
- 2000-11-30 ZA ZA200007059A patent/ZA200007059B/en unknown
- 2000-12-14 NO NO20006378A patent/NO328417B1/no not_active IP Right Cessation
2003
- 2003-03-11 US US10/386,999 patent/US7579366B2/en not_active Expired - Fee Related
2006
- 2006-12-20 CY CY20061101818T patent/CY1105863T1/el unknown
2007
- 2007-04-23 IL IL182744A patent/IL182744A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
SK285647B6 (sk)	2007-05-03
SK19712000A3 (sk)	2001-09-11
RU2227142C2 (ru)	2004-04-20
ID28210A (id)	2001-05-10
TR200003844T2 (tr)	2001-04-20
IL139784A0 (en)	2002-02-10
HUP0102711A3 (en)	2002-09-30
AU4774899A (en)	2000-01-10
US7579366B2 (en)	2009-08-25
CN1306531A (zh)	2001-08-01
PL197648B1 (pl)	2008-04-30
NO20006378L (no)	2001-02-21
JP4681732B2 (ja)	2011-05-11
ZA200007059B (en)	2002-01-30
CN1192031C (zh)	2005-03-09
CA2334342A1 (en)	1999-12-29
PT1089998E (pt)	2007-01-31
WO1999067252A3 (en)	2000-03-16
US6380394B1 (en)	2002-04-30
US6531497B1 (en)	2003-03-11
BR9911420A (pt)	2001-03-20
SK287864B6 (sk)	2012-02-03
PL345327A1 (en)	2001-12-17
IL139784A (en)	2010-05-17
EP1089998A2 (de)	2001-04-11
DE69933767T2 (de)	2007-09-13
CA2334342C (en)	2012-07-17
DE69933767D1 (de)	2006-12-07
JP2002518504A (ja)	2002-06-25
CZ20004769A3 (cs)	2001-07-11
IL182744A (en)	2010-05-17
WO1999067252A2 (en)	1999-12-29
NO328417B1 (no)	2010-02-15
US20030203938A1 (en)	2003-10-30
ATE343573T1 (de)	2006-11-15
NZ508622A (en)	2003-07-25
ES2273502T3 (es)	2007-05-01
IL182744A0 (en)	2007-07-24
EP1089998B1 (de)	2006-10-25
AU757854B2 (en)	2003-03-06
EP1741715A1 (de)	2007-01-10
KR20010083060A (ko)	2001-08-31
HUP0102711A2 (hu)	2001-12-28
CZ301783B6 (cs)	2010-06-23
KR20080045298A (ko)	2008-05-22
HK1038358A1 (en)	2002-03-15
CY1105863T1 (el)	2011-02-02
MXPA00012443A (es)	2004-12-03
KR20090066332A (ko)	2009-06-23
KR100864742B1 (ko)	2008-10-22
NO20006378D0 (no)	2000-12-14

Publication	Publication Date	Title
NO20006378D0 (no)	2000-12-14	Epotilonderivater samt deres syntese og anvendelse
LU91210I2 (fr)	2006-11-06	Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
DE69725113D1 (de)	2003-10-30	Azetidin- und Pyrrolidinderivate
ATE125539T1 (de)	1995-08-15	1,4-benzothiazedinderivat.
DE69907331D1 (de)	2003-06-05	Fungizide Zusammensetzung enthaltend ein 1,2,3-Thiadiazolderivat sowie deren Verwendung
ATE197710T1 (de)	2000-12-15	Chinazolin-derivate
ATE159885T1 (de)	1997-11-15	Fungizide zusammensetzungen
ATE134364T1 (de)	1996-03-15	Phenylthioharnstoffderivate und ihre pharmazeutische verwendung
FI852223L (fi)	1985-12-08	Saosom fungicider anvaenda triazoler.
PL352613A1 (en)	2003-08-25	Derivatives of benzamide, insecticides for agriculture and horticulture as well as their application
LV10076A (lv)	1994-05-10	Aizvietoti beta- diketoni
ATE137759T1 (de)	1996-05-15	S'-adenosyl-methionin-decarboxylase-inhibitoren
NO175253C (no)	1994-09-21	Forbindelse, anvendelse og preparat
NO921282D0 (no)	1992-04-02	Benzotiazolderivater og deres anvendelse
ATE105565T1 (de)	1994-05-15	Pradimicinderivate.
DK0641794T3 (da)	2000-11-13	Thienyl- og furylpyrrolderivater, deres fremstilling samt deres anvendelse som insecticider og acaricider
DK0745680T3 (da)	2000-10-02	Nye fungicide midler LL-15G256 gamma, delta, og epsilon produceret af LL-15G256 (Hypoxylon oceanicum)
ATE172842T1 (de)	1998-11-15	Schutz gegen mikroorganismen auf pflanzen mit 1- hydroxymethylpyrazolen